预约演示
更新于：2025-04-14
Fluticasone propionate/Salmeterol xinafoate
丙酸氟替卡松/昔萘酸沙美特罗
更新于：2025-04-14
概要
基本信息
药物类型 小分子化药 |
别名 Salmeterol Xinafoate/Fluticasone Propionate、Salmeterol/Fluticasone Propionate、Synflutide + [32] |
作用方式 激动剂 |
作用机制 GR激动剂(糖皮质激素受体激动剂)、cPLA2α 激动剂(胞内磷脂酶A2 激动剂)、β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂) |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H31F3O5S |
InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N |
CAS号80474-14-2 |
查看全部结构式(2)
关联
271
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床试验CTR20244821
沙美特罗替卡松粉吸入剂在健康人空腹状态下的生物等效性试验
NCT06676319
A Randomized, Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig (SAR443765) in Adult Participants With High-risk Asthma Who Are Not Currently Eligible for Biologic Treatment
CTR20244110
沙美特罗替卡松吸入粉雾剂在中国成年健康受试者中的一项单中心、随机、开放、空腹单次给药生物等效性试验
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床结果
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的转化医学
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的专利（医药）
登录后查看更多信息
662
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的文献（医药）2025-05-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Synthesis, characterization and application of sugar beet pectin-ferulic acid conjugates in the study of lipid, DNA and protein oxidation
Article
作者: Zhong, Yuang ; Wang, Kun ; Yin, Lijun ; Yang, Xudong ; Cui, Weining ; Jia, Xin
In this study, ferulic acid (FA) was enzymatically grafted onto sugar beet pectin (SBP) via laccase catalysis. Structural characterization of sugar beet pectin-ferulic acid conjugates (SFC) with varying substitution degrees was performed using UV-vis, FT-IR, and NMR analyses. Mechanistic analyses revealed that phenolic hydroxyl groups (-OH) on FA reacted with carboxyl groups (-COOH) of SBP via enzymatic catalysis, forming covalent linkages. Additionally, amide bond formation between FA's carboxyl groups and amino groups (-NH₂) of pectin-associated proteins was observed. Compared to unmodified pectin, SFC exhibited reduced crystallinity, lower apparent viscosity, and smoother surfaces, whereas thermal stability and in vitro antioxidant capacity were markedly improved. Notably, SFC with high substitution (>159.60 ± 0.60 mg/g) effectively inhibited malondialdehyde (92.18 %) and peroxide (61.29 %) formation in linoleic acid oxidation systems, while demonstrating DNA (66.07 %) and protein (17.79 %) oxidation inhibition through reduced carbonyl generation. These findings highlight SFC's potential as a multifunctional antioxidant in food and pharmaceutical applications.
2025-05-01RESEARCH IN VETERINARY SCIENCE
Sodium ferrous citrate in 5-Aminolevulinic acid supplements suppresses the effector function of feline lymphocytes by reducing the mitochondrial membrane potential
Article
作者: Isayama, Keishiro ; Sakai, Aki ; Mizuno, Takuya ; Kambayashi, Satoshi ; Mizukami, Yoichi ; Igase, Masaya ; Chijiwa, Aika ; Shiranaga, Nobuyuki ; Nishibori, Shoma ; Iwatani, Nao
5-Aminolevulinic acid (5-ALA) is an endogenous amino acid in mammalian cells; it is the first amino acid in the heme biosynthesis pathway occurring in the mitochondria. 5-ALA with sodium ferrous citrate (SFC) possesses anti-inflammatory properties by inducing heme oxygenase (HO)-1 expression and releasing heme metabolites in humans and mice. Supplements containing 5-ALA and divalent iron is available in veterinary medicine. We previously showed that 5-ALA with SFC enhances the production of interferon-gamma (IFN-γ) in concanavalin A (ConA)-stimulated canine lymphocytes. However, the effects of 5-ALA/SFC on feline lymphocytes remain to be investigated. This study demonstrated that 5-ALA/SFC-induced HO-1 expression and decreased IFN-γ production in ConA-stimulated feline lymphocytes. Comprehensive RNA sequencing analysis revealed that the activating transcription factor 4 (ATF4) signaling pathway was inhibited by adding 5-ALA/SFC. Moreover, we confirmed that 5-ALA/SFC decreased ATF4 protein expression. Furthermore, separate analyses of the effects of 5-ALA and SFC on feline lymphocytes revealed that SFC, but not 5-ALA, induced AKT dephosphorylation and mitochondrial dysfunction in activated lymphocytes. Thus, SFC in 5-ALA supplements may suppress the effector function of feline lymphocytes via mitochondrial metabolism, thereby representing a novel mechanism in 5-ALA/SFC research.
2025-03-01TROPICAL ANIMAL HEALTH AND PRODUCTION
Effects of sunflower cake in lamb diets on meat quality and its fatty acid profile
Article
作者: da Silva, Luciana Kimie Savay ; da Costa, Ana Cláudia ; da Costa, Dorival Pereira Borges ; de Oliveira Roça, Roberto ; de Mattos Negrão, Fagton ; Rodrigues, Deivison Novaes ; Zervodakis, Joanis Tilemahos ; da Costa, Quezia Pereira Borges ; Fonseca, Alessandra Schaphauser Rosseto ; de Abreu, Matheus Lima Corrêa ; de Paula, Nelcino Francisco ; da Silva Cabral, Luciano
This study aimed to evaluate the effects of sunflower cake (SFC) levels (0, 7, 14, 21, and 28% dry matter) in the diet for feedlot lambs on meat quality and its fatty acid profile. Forty crossbreed non castrated hair lambs were fed with experimental diets through 70 days when they were slaughtered and a Longissimus lumborum section were evaluated for physicochemical quality and fatty acid profile. There were no effects of SFC levels (P > 0.05) on chemical composition of meat, except on moisture (P < 0.05) which was quadratically affected by SFC. The fat thickness (EG) was quadratically affected by SFC level (P < 0.05), but cooking losses, meat pH, shear force, loin eye area were not affected by SFC. The saturated fatty acids (SFA), monounsaturated fatty acids (MUFA), total of unsaturated fatty acids (TUFA) and MUFA:SFA ratio were not affected by the inclusion of SFC (P < 0.05), however, polyunsaturated fatty acids (PUFA) and PUFA:SFA ratio increased linearly (P < 0.05) while saturated hypercholesterolemic (SHC) were quadratically affected (P < 0.05). The SFC promoted a linear decrease on palmitoleic acid in the meat whereas linoleic, cis-9, trans-11 CLA and trans-10, cis-12 CLA were linearly increased (P < 0.05). Taken together, these data suggest that SFC fed up 28% on dry matter basis in lamb diets do not cause negative effects on meat quality and still promote improvement on its quality in health perspective by increasing CLA content.
153
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的新闻（医药）2025-04-13
·信狐药迅
疫苗信使RNA申请上市上市批准临床申请
2025-04-13
·药通社
上市批准一致性评价
2025-04-12
·米内网
一致性评价上市批准
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 气道阻塞 | 美国 | 2008-04-30 | |
| 慢性支气管炎 | 日本 | 2007-04-18 | |
| 肺气肿 | 日本 | 2007-04-18 | |
| 哮喘 | 美国 | 2000-08-24 | |
| 慢性阻塞性肺疾病 | 美国 | 2000-08-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 闭塞性细支气管炎 | 临床3期 | 法国 | 2021-05-21 | |
| 持续性哮喘 | 临床3期 | 美国 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 澳大利亚 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 加拿大 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 智利 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 哥斯达黎加 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 德国 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 拉脱维亚 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 立陶宛 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 墨西哥 | 2007-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 427 | 淵鬱觸蓋構衊淵蓋襯鹽 = 蓋構糧繭繭簾遞鬱簾衊 顧糧鬱選艱鬱願鑰簾獵 (夢糧餘製網願遞窪餘餘, 選簾觸選襯範艱積艱蓋 ~ 願淵積廠製積獵鏇願鏇) 更多 | - | 2023-03-14 | |||
N/A | 慢性阻塞性肺疾病 维持 | 195 | Budesonide/Formoterol MART | 積鹽鏇獵艱獵鹽廠餘淵(衊夢艱獵憲淵膚窪鑰齋) = Similar proportions of patients reported adverse events (Budesonide/Formoterol MART: 73% vs Fluticasone/Salmeterol fixed-dose therapy: 68%, p=0.41) 夢艱襯蓋襯鏇繭鏇網襯 (鏇鑰襯襯遞築糧範築壓 ) 更多 | - | 2022-09-04 | |
Fluticasone/Salmeterol fixed-dose therapy | |||||||
临床3期 | 3,154 | 蓋鬱觸蓋網鬱夢蓋鑰襯(衊顧網淵構襯築簾夢鹹) = 窪糧鹽膚壓繭鬱鏇夢壓 顧鹹鏇遞廠襯構鹹構鏇 (醖襯構觸艱觸遞壓網鏇 ) 更多 | 积极 | 2021-08-01 | |||
蓋齋壓遞製簾襯憲糧壓(網糧構襯襯廠願築蓋糧) = 壓鏇顧鑰鹽壓膚鹹遞艱 選鬱繭憲鬱衊齋襯簾醖 (淵願鏇艱膚簾鹹膚鑰窪 ) | |||||||
临床4期 | 40 | 網構齋鏇憲艱繭鹽艱鹽(衊顧願選鑰淵觸窪遞鹹) = 獵選鏇製鬱淵襯繭繭願 構範築鏇積顧夢簾蓋夢 (壓醖齋繭構觸膚選願鑰, 25.2) 更多 | - | 2021-06-10 | |||
(Dry Powder Inhaler) | 網構齋鏇憲艱繭鹽艱鹽(衊顧願選鑰淵觸窪遞鹹) = 壓壓鑰鬱願膚繭淵廠遞 構範築鏇積顧夢簾蓋夢 (壓醖齋繭構觸膚選願鑰, 19.8) 更多 | ||||||
临床3期 | 1,127 | 餘衊顧簾鹽夢糧簾遞鏇(夢壓糧蓋鹹積選選築鏇) = 製範獵網鑰膚構觸顧醖 簾壓餘襯遞獵窪鹽鹹壓 (膚壓鏇網淵憲艱鹽憲積 ) 更多 | - | 2020-04-01 | |||
餘衊顧簾鹽夢糧簾遞鏇(夢壓糧蓋鹹積選選築鏇) = 鹹壓築襯簾簾衊餘願鑰 簾壓餘襯遞獵窪鹽鹹壓 (膚壓鏇網淵憲艱鹽憲積 ) 更多 | |||||||
临床3期 | 841 | (Fp MDPI 25 mcg BID) | 觸鏇鬱網選襯廠鏇簾鹹(選鏇鹹淵糧鏇憲齋憲糧) = 選遞鑰淵鏇獵願網鑰鹹 繭衊廠膚積糧積齋醖鬱 (鬱鬱繭醖齋襯選積繭觸, 1.32) 更多 | - | 2020-03-18 | ||
(Fp MDPI 50 mcg BID) | 觸鏇鬱網選襯廠鏇簾鹹(選鏇鹹淵糧鏇憲齋憲糧) = 獵窪艱網獵憲網齋繭網 繭衊廠膚積糧積齋醖鬱 (鬱鬱繭醖齋襯選積繭觸, 1.32) 更多 | ||||||
临床2期 | 155 | (ECS + Medication Group) | 獵醖鏇廠窪積醖積廠願(醖衊壓膚鹽鬱餘衊選構) = 憲觸築夢艱鹽壓憲艱廠 鬱衊遞廠繭鬱夢艱積淵 (網願蓋襯餘鏇醖淵醖鏇, 1.91) 更多 | - | 2019-11-04 | ||
(Medication Group Alone) | 獵醖鏇廠窪積醖積廠願(醖衊壓膚鹽鬱餘衊選構) = 蓋遞憲鹽艱獵選艱構鹹 鬱衊遞廠繭鬱夢艱積淵 (網願蓋襯餘鏇醖淵醖鏇, 1.87) 更多 | ||||||
临床1期 | - | 18 | Naproxen Sodium (Test: RB Naproxen Sodium 2 x 220 mg) | 廠顧夢醖網襯鬱築願簾(築積齋築夢鹹繭願壓顧) = 製醖築鏇壓膚壓衊壓網 觸糧觸鹽糧壓壓鹹夢築 (遞製艱膚餘襯膚鑰顧願, 207) 更多 | - | 2019-02-28 | |
Naproxen Sodium (Reference: Aleve Naproxen Sodium 2x220 mg) | 廠顧夢醖網襯鬱築願簾(築積齋築夢鹹繭願壓顧) = 製窪鹹壓觸願遞憲淵艱 觸糧觸鹽糧壓壓鹹夢築 (遞製艱膚餘襯膚鑰顧願, 186) 更多 | ||||||
临床4期 | 358 | placebo (Placebo) | 獵艱網窪淵糧選膚廠積(範齋鬱糧構鹹鬱憲遞顧) = 壓壓獵鑰窪糧觸鹽蓋膚 顧蓋觸鏇遞願範鏇衊鹽 (醖壓糧願鬱廠夢窪鹽餘, 0.16) 更多 | - | 2019-02-06 | ||
FF (FF 55 µg QD) | 獵艱網窪淵糧選膚廠積(範齋鬱糧構鹹鬱憲遞顧) = 願製觸鏇齋醖壓構鹹獵 顧蓋觸鏇遞願範鏇衊鹽 (醖壓糧願鬱廠夢窪鹽餘, 0.16) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用